CLINICAL TRIALS PROFILE FOR HYDROCORTISONE ACETATE; UREA
✉ Email this page to a colleague
All Clinical Trials for Hydrocortisone Acetate; Urea
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00915343 ↗ | Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency | Completed | Shire | Phase 2/Phase 3 | 2007-08-21 | This is a randomised, controlled, open, two-armed, two-period cross-over, multi-centre phase II/III study to assess the safety, tolerability and pharmacokinetics of once-daily oral modified-release hydrocortisone in comparison to conventional thrice-daily oral hydrocortisone tablets in patients with adrenal insufficiency |
| NCT01014364 ↗ | Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu | Terminated | Assistance Publique - Hôpitaux de Paris | Phase 3 | 2010-03-01 | The H1N1 flu pandemic is one of the major infectious threat of the past half century. it is rapidly progressing worldwide and a substantial number of patients get severe H1N1 related pneumonia that requires mechanical ventilation and admission to the intensive care unit. The acute respiratory distress syndrome is associated with a substantial mortality and morbidity partly as a consequence of uncontrolled lung and systemic inflammation. many physicians are trying to counteract this pro-inflammatory storm by the use of corticosteroids albeit these drugs may cause super infection or metabolic disorders. Thus, there is a need for a randomized double blind, placebo controlled trial to define the benefit to risk ratio of corticosteroids in this patient. |
| NCT01014364 ↗ | Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu | Terminated | University of Versailles | Phase 3 | 2010-03-01 | The H1N1 flu pandemic is one of the major infectious threat of the past half century. it is rapidly progressing worldwide and a substantial number of patients get severe H1N1 related pneumonia that requires mechanical ventilation and admission to the intensive care unit. The acute respiratory distress syndrome is associated with a substantial mortality and morbidity partly as a consequence of uncontrolled lung and systemic inflammation. many physicians are trying to counteract this pro-inflammatory storm by the use of corticosteroids albeit these drugs may cause super infection or metabolic disorders. Thus, there is a need for a randomized double blind, placebo controlled trial to define the benefit to risk ratio of corticosteroids in this patient. |
| NCT01055249 ↗ | UVB Model Validation Study | Completed | X-pert Med GmbH | Phase 1 | 2010-01-01 | Single centre, subject and observer blinded, placebo controlled, cross-over study of the effect of oral ibuprofen and topical hydrocortisone-21-acetate on ultraviolet radiation (UVR) induced pain and inflammation in healthy volunteers conducted in two segments and using an intra-individual comparison of application areas. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Hydrocortisone Acetate; Urea
Condition Name
Clinical Trial Locations for Hydrocortisone Acetate; Urea
Trials by Country
Clinical Trial Progress for Hydrocortisone Acetate; Urea
Clinical Trial Phase
Clinical Trial Sponsors for Hydrocortisone Acetate; Urea
Sponsor Name
